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Intravitreal administration is the method of choice in drug delivery to the retina and/or choroid. Rabbit is
the most commonly used animal species in intravitreal pharmacokinetics, but it has been criticized as
being a poor model of human eye. The critique is based on some anatomical differences, properties of the
vitreous humor, and observed differences in drug concentrations in the anterior chamber after intra-
vitreal injections. We have systematically analyzed all published information on intravitreal pharma-
cokinetics in the rabbit and human eye. The analysis revealed major problems in the design of the
pharmacokinetic studies. In this review we provide advice for study design. Overall, the pharmacokinetic
parameters (clearance, volume of distribution, half-life) in the human and rabbit eye have good corre-
lation and comparable absolute values. Therefore, reliable rabbit-to-man translation of intravitreal
pharmacokinetics should be feasible. The relevant anatomical and physiological parameters in rabbit and
man show only small differences. Furthermore, the claimed discrepancy between drug concentrations in
the human and rabbit aqueous humor is not supported by the data analysis. Based on the available and
properly conducted pharmacokinetic studies, the differences in the vitreous structure in rabbits and
human patients do not lead to signiﬁcant pharmacokinetic differences. This review is the ﬁrst step to-
wards inter-species translation of intravitreal pharmacokinetics. More information is still needed to
dissect the roles of drug delivery systems, disease states, age and ocular manipulation on the intravitreal
pharmacokinetics in rabbit and man. Anyway, the published data and the derived pharmacokinetic
parameters indicate that the rabbit is a useful animal model in intravitreal pharmacokinetics.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
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Ltd. This is an open access article uvarious rare ocular diseases may impair the functionality of the
retina leading to visual impairment and blindness. Even though this
is a growing problem in the aging populations, effective treatments
are not available to most patients with retinal diseases.
New mechanisms of action and drug candidates are being
discovered for the retinal diseases (Zhang et al., 2012), but drug
delivery to the retina is very difﬁcult (and often impossible) from
topical eye drops or systemic medications (such as tablets).
Therefore, the intravitreal injections have emerged as the primary
method of drug administration to the retina and choroid (del Amo
and Urtti, 2008; Urtti, 2006). The number of annual intravitreal
injections has increased rapidly being nearly 400,000 in the United
Kingdom (Severn and Hamilton, 2015) and probably an order of
magnitude higher numbers in Europe and U.S.A. For example,
bevacizumab (Avastin®), ranibizumab (Lucentis®), pegaptanib so-
dium (Macugen®), aﬂibercept (Eylea®) and triamcinolone aceto-
nide (Kenalog®) are widely used as intravitreal injections to treat
neo-vascular macular degeneration and other retinal diseases.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dosing intervals should be long. The dosing intervals of intravitreal
injections of antibodies, aptamers, soluble receptors and suspen-
sions are often four to six weeks and sometimes even twelve weeks
(Bashshur et al., 2008; Cheung and Eaton, 2013). This is based on
the slow clearance, long half-life (about two to six days) and
extremely high potency the macromolecules (anti-VEGF antibodies
and soluble receptors) or slow dissolution and long residence time
of suspension particles (corticosteroid suspensions). However, in
the case of intravitreal solutions of small molecular drugs, the fast
elimination rates (half-lives of 1e27 h) would lead to frequently
repeated injections that are not possible in the clinical setting.
Moreover, injections of the drug solutions intravitreally lead to high
ﬂuctuations in intravitreal drug concentrations. This is feasible only
for the drugs with wide therapeutic index, otherwise the adverse
effects would prohibit the clinical use. Controlled release formu-
lations canmaintain the intravitreal drug concentrations within the
therapeutic index for prolonged periods, thereby allowing long
dosing intervals of several months. Some controlled release im-
plants are already in the clinical use for instance, ﬂuocinolone
acetonide intravitreal implant (Iluvien®) and dexamethasone
intravitreal implant (Ozurdex®) (del Amo and Urtti, 2008; Sanford,
2013; Totan et al., 2015). Estimation of the time course of drug ef-
fects in the posterior eye segment is possible with pharmacokinetic
modeling tools (Kontturi et al., 2014; Stewart and Rosenfeld, 2008).
After intravitreal administration, drugs distribute to the ocular
tissues (lens, iris, ciliary body, retina). Distribution depends on the
ability of drug to partition into the tissues and it is described as
volume of drug distribution. Drug elimination may take place
posteriorly through the blood-retina barrier (Duvvuri et al., 2003;
Gupta et al., 2000; Maurice and Mishima, 1984; Shen et al., 2007)
to the choroidal blood circulation that constitutes most of the
ocular blood ﬂow (del Amo et al., 2015; Roh et al., 2006). Intra-
vitreal drug is eliminated also anteriorly via aqueous humor turn-
over and uveal blood ﬂow. The importance of anterior and posterior
routes depends on the drug properties (Maurice and Mishima,
1984): lipophilic drugs with high permeability in the blood-retina
barrier are mostly eliminated posteriorly (e.g. ﬂuconazole; vitreal
clearance 0.753 ml/h (Gupta et al., 2000)), whereas elimination of
large and hydrophilic compounds is restricted to the anterior route
(e.g. bevacizumab; vitreal clearance 0.019 ml/h (Bakri et al., 2007;
Christoforidis et al., 2011; del Amo et al., 2015)). These processes
determine drug elimination in rabbit and human eyes and it is
described as intravitreal clearance. Ocular pharmacokinetic pa-
rameters (i.e. volume of distribution and clearance) are the most
informative, reliable and quantitative basis for the pharmacokinetic
comparisons in terms of species, disease states, age, drug com-
pounds and delivery systems.
Ocular pharmacokinetics has only rarely been studied in the
human eye, because the invasive sampling from the human eye is
ethically restricted andmay inﬂuence pharmacokinetics. Therefore,
ocular pharmacokinetics relies on animal models, mostly rabbits.
Recently, the rabbit eye has been criticized for being a poor model
of the human eye (Laude et al., 2010; Rowe-Rendleman et al., 2014).
Therefore, we investigated all available intravitreal pharmacoki-
netic data in rabbits (del Amo et al., 2015) and humans (this review)
and derived the pharmacokinetic parameters (clearance, volume of
distribution) to compare systematically intravitreal pharmacoki-
netics in man and rabbit. We did not ﬁnd any convincing evidence
to justify the criticism of the rabbit model. Moreover, during the
process of analyzing the intravitreal pharmacokinetic parameters
in the rabbit eyes (del Amo et al., 2015), we noticed another
remarkable problem: many published studies are based on sub-
optimal study designs, and actually 58% of the studies were dis-
carded from the pharmacokinetic data analysis.In this review, we summarize the current knowledge of intra-
vitreal pharmacokinetics in rabbits and humans, and provide
advice in intravitreal pharmacokinetic study design.2. Intravitreal pharmacokinetics in rabbit eye
2.1. Introduction of concepts
The intravitreal pharmacokinetics is deﬁned by the primary
parameters: volume of distribution (Vss, ivt) and clearance (CLivt)
that describe drug distribution and elimination, respectively.
Vss, ivt can be compared to the anatomical volumes of the ocular
tissues based on the principles from the drug distribution from
plasma to the tissues (Jusko, 2006; Mager, 2006):
Vss; ivt ¼ Vvitreous þ Vlens  Kp; lens þ Vciliary body  Kp; ciliary body
þ Vretina  Kp; retina…
(1)
where V values indicate the anatomical tissue volumes and Kp
distribution coefﬁcients of the drug between the tissue and vitre-
ous. High Kp values indicate effective drug partitioning to the tis-
sues, leading to Vss, ivt values bigger than the anatomical volumes.
Systemic volume of drug distribution at steady-state can be
related to the anatomical volumes using Gillette equation (Gillette,
1971; Mager, 2006). In this case, the equation for the intravitreal
drug delivery would be:
Vss; ivt ¼ Vvitreous þ Vlens 
fu; vitreous
fu; lens
þ Vciliary body 
fu; vitreous
fu; ciliary body
þ Vretina 
fu; vitreous
fu; retina
…
(2)
where V values indicate the anatomical tissue volumes and fu terms
indicate the fractions of unbound drug in the vitreous and sur-
rounding tissues. Thus, in the context of intravitreal administration,
Vss, ivt is related to the anatomical volumes (Vvitreous, Vtissues) and
either 1) drug distribution between the tissues and vitreous humor
(Kp) or 2) free fractions of the drug in the vitreous (fu, vitreous) and
tissues (fu, tissue). Anyway, in both cases, high drug concentrations in
the tissues increase the value of Vss, ivt.
CLivt can be related to the ocular ﬂows:
CLivt ¼ Q ocular  E ocular (3)
where Q is the ocular ﬂow and E is the extraction ratio in the tissue
(0 < E < 1). Theoretical maximum for CLivt is equal to the ocular
ﬂows (aqueous humor and blood ﬂows) representing completely
ﬂow-limited clearance without any membrane barrier limitations
(e.g. blood-retinal barrier). On the contrary, at low values of E the
clearance is limited by membrane permeation and deﬁned as
product of drug permeability in the membrane (P) and the mem-
brane surface area (S):
CLivt ¼ P ocular barriers  S ocular barriers (4)
After intravitreal injection, the drug is partitioning to some
extent to the surrounding tissues and eliminated from the vitreous
through aqueous humor turnover and blood-ocular barriers (Fig. 1).
Membrane permeable drugs can cross the blood-ocular barriers,
while poorly permeable drugs (e.g. macromolecules) will be
cleared via aqueous humor turnover (Maurice and Mishima, 1984).
All intravitreal drug will eventually end-up to the systemic
Fig. 1. Routes of drug elimination after intravitreal injection. (A) Anterior elimination of the drug in the aqueous humor ﬂow (1). (B) Drug elimination through blood-ocular barriers.
The drug permeates through the posterior iris epithelium into iris vein and is drained by vortex veins (2), through the non-pigmented ciliary epithelium to ciliary muscles and from
the ciliary plexus to the episcleral veins (3), to the retinal capillaries and through the retinal pigment epithelium (RPE) into the choroid and systemic circulation (4) (del Amo et al.,
2015).
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fate. However, the systemic circulation can be handled as a sink
because the clearance in the human systemic circulation is much
higher (10e100,000 ml/h) than the clearance in the eye
(0.01e1.0 ml/h). Therefore, the concentrations in the systemic cir-
culation are orders of magnitude lower than in the eye, and drug
elimination from the eye is rate-limited by the ocular processes,
and not affected by the drug concentrations in the blood
circulation.
The primary pharmacokinetic parameters Vss, ivt and CLivt are
useful in pharmacokinetic simulations and clinical translation. They
allow estimation of average steady-state concentrations, concen-
tration proﬁles, half-life (t1/2, ivt) and amount of drug in the eye after
administration of different doses or dosage forms (del Amo et al.,
2015). Vss, ivt and CLivt can be linked to the fundamental factors,
anatomy, physiology, and drug interactions with tissues, thereby
providing understanding of ocular pharmacokinetics in the physi-
ological context and generating tools for bottom-up simulation
models (del Amo et al., 2015). Noteworthy, the most frequently
used intravitreal pharmacokinetic parameter, t1/2, ivt depends on
both drug distribution and elimination,
t1=2; ivt ¼
ln2  Vss; ivt
CL ivt
(5)
if the intravitreal concentration proﬁle showsmulti-exponential
decline, the t1/2, ivt correspond to effective t1/2, ivt. Even though
t1/2, ivt is useful in deﬁning the dosage intervals of the drug, it does
not allowmechanistic analyses and simulations. Half-life cannot be
linked to physiology and pathophysiological alterations in the eye.2.2. Analysis of the literature
Recently, we developed a universal collection of Vss, ivt, CLivt and
t1/2, ivt values (del Amo et al., 2015). For that, we carried out a
comprehensive literature search on intravitreal pharmacokinetic
studies in healthy and normal rabbit eyes during 1947e2013. We
set criteria for the data quality: at least four time-points, at least
two replicates per point, and balanced sampling for at least a time-
span of two t1/2, ivt of the drug (the derived parameters values are
presented later in the Section 2.4). The criteria are needed for
reliable determination of Vss, ivt, CLivt and t1/2, ivt values. Surpris-
ingly, only 42% of the literature reports fulﬁlled these qualitycriteria. The corresponding references and the data analysis are
presented in our previous paper (del Amo et al., 2015). The
remaining 58% (92 reports) had to be discarded due to inadequate
data points or other problems (e.g. analytical issues, poor match
between dose and initial concentration, solubility problems) that
prevent reliable data analysis. Commonly, the problems were
related to inadequate number of data points, poorly selected time
spans and narrow concentration ranges. Table 1 illustrates some
data quality problems that hamper the calculation of the pharma-
cokinetic parameters (Vss, ivt, CLivt and t1/2, ivt) or lead to unreliable
estimates. For the analysis Phoenix WinNonlin® software (version
6.3, Pharsight Inc., St. Louis, USA) was used and accurate description
of the workﬂow is described in Section 2.3.
Even though many intravitreal pharmacokinetic studies did not
meet the normal quality standards, they give rough estimates of
t1/2, ivt and range of drug concentrations after injection of a certain
dose. Such information is valuable and important, but unfortu-
nately not adequate for determination of pharmacokinetic param-
eters accurately.2.3. Design of an intravitreal pharmacokinetic study
In a typical intravitreal pharmacokinetic study, drug is injected
into the vitreal cavity in rabbits and, thereafter, drug concentrations
are determined periodically. In most studies, the animals are
sacriﬁced at different time intervals: the eyes are removed and the
vitreous humor samples are assayed for drug concentrations.
Continuous sampling with a microdialysis probe in the rabbit eyes
has also been used (Atluri and Mitra, 2003). This approach reduces
the number of animals, but reliable recovery estimates are needed
in the determination of the drug yield (Duvvuri et al., 2003) and the
duration of the experiments is often limited. In some cases, a
radioactively labeled drug has been injected to the vitreous fol-
lowed by imaging with positron emission tomography
(Christoforidis et al., 2011, 2012). In all cases, the sampling times are
crucial for obtaining reliable pharmacokinetic proﬁles and param-
eter values.
In rabbit studies, the number of test animals should be mini-
mized based on 3R (Reduce, Reﬁne, Replace) principles, but this
should not lead to inadequate experimental design, unreliable
pharmacokinetic proﬁles and parameters (Section 2.2.). Good
practices of systemic pharmacokinetic data analyses should be
applied with some modiﬁcations in ocular pharmacokinetics. The
Table 1
Typical examples of intravitreal data that cannot be used for reliable estimation of pharmacokinetic parameters are illustrated. These literature datawere used for parameter estimationwith Phoenix software following the advice
from Section 2.3. The calculation of the estimated concentration at time 0 (C0) is based on 1.15 ml rabbit vitreous volume (del Amo et al., 2015).
a: The range values of Vss, ivt and CLivt in rabbit vitreous is 0.72e3.14 ml and 0.011e1.530 ml/h respectively (Fig. 2 and del Amo et al., 2015).
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Table 2
Pharmacokinetic data analysis with curve ﬁtting software.
Compartmental model
Select one- or two- compartmental model.
The experimental data are plotted in semi-logarithmic plot: logarithm of intravitreal concentration vs time.
Based on the shape of the plotted data one-compartmental (single slope) or two-compartmental (two distinct slopes) model may be feasible.
Weighting factor
Weighting is used to improve the curve ﬁtting by giving more weight to the last data points with low concentrations.
The sum of squared residuals can be weighted by
 one (uniform weighting)
 1/Cobs or 1/Ccalc (1/Y or 1/Yhat respectively)
 1/(Cobs)2 or 1/(Ccalc)2 (1/Y2 or 1/Yhat2 respectively)
The relative weight of small concentrations is increased with the use of the concentration or squared concentration in the denominator.
Y is the actual concentration and Yhat is the predicted concentration.
Goodness of ﬁt
Goodness of ﬁt describes how close the calculated curve is to the data points. The following criteria is used to evaluate the goodness of ﬁt:
1) Calculated concentration curve should lie between the observed concentration points.
2) Signs of the residuals (i.e., Cobs e Ccalc, shows either over-estimation or under-estimation) must change randomly. This indicates lack of systematic deviations.
3) Relative residuals (residual/Cobs) are not excessive at low concentrations.
4) Conﬁdence intervals of the parameters are positive. This depends on the number of animals and data points, and the complexity of the pharmacokinetic model.
5) Coefﬁcient of variation (CV%) should be less than 30%, preferably below 10%.
6) Correlation between various pharmacokinetic parameters should be < 0.95. This informs us that the parameters are independent from each other.
7) Sum of weighted squared residuals should be small enough.
8) Akaike's information criterion (AIC) is used to discriminate between models (for example, one- and two-compartment models) with the same weighting. The best
model has the lowest AIC value.
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software (e.g. Kinetica®, Thermo Fisher Scientiﬁc Inc, Waltham, USA or
Phoenix WinNonlin® software) that are based on the method of least
squares to ﬁt the concentration curves. The objective is to minimize
the difference between the observed and calculated concentrations
(Cobs and Ccalc respectively), i.e. sum of squared residuals S(Cobs e
Ccalc)2. These methods pool all the data from the experiment for
maximal information gain. As illustrated in Table 1 inadequate data
may not allow reliable estimation of pharmacokinetic parameters.
Proper procedure in pharmacokinetic data analysis is presented in
Table 2.
Usually, the kinetic analysis is done for each individual sepa-
rately (e.g. plasma samples at different times), but this is not
possible in intravitreal studies, because multiple sampling from the
vitreous is not possible. All individual data points can be ﬁtted
simultaneously, and the ﬁtted curve can be compared to the
observed mean values or individual points. In any case, it is
important to have adequate number of data points with proper
time span and concentration range.
We propose that the following points should be taken into
account in the design of intravitreal pharmacokinetic studies.
Firstly, the drug dose should be soluble in the formulation and in
the vitreous. This is not the case in many studies (some examples
(Chin et al., 2005; Doft et al., 1985; Wingard et al., 1989)). Then,
the resulting data does not allow reliable determination of CLivt,
Vss, ivt and t1/2, ivt for the drug. Anyway, the obtained concentra-
tion proﬁles describe the properties of the formulation in drug
delivery. Secondly, the dose should be reported, and if the drug is
in salt form, the reporting should allow the estimation of dose as
free acid or free base. Thirdly, at least six time points must be
used at properly balanced intervals to describe drug distribution
and elimination. The ﬁrst data point should be shortly after in-
jection and, thereafter, the data points should span at least three
t1/2, ivt of the drug (i.e. at least 87% of the drug has been elimi-
nated at that point). Fourthly, at least four to six replicate eyes
should be used for each time point. Overall, this will results in
24e36 rabbit eyes (12e18 animals). Within the European Union
the use of animals in scientiﬁc experiments should be rationally
reduced (Directive 86/609/EEC). Properly conducted intravitreal
pharmacokinetic study uses many rabbits, but it will yield reliable
quantitation of pharmacokinetics (incl. Vss, ivt, CLivt, t1/2, ivt) that
allows estimation of drug concentrations at different dosingregimens thereby reducing the need of animals in later experi-
ments and in the long run.
2.4. Intravitreal pharmacokinetic parameters in rabbits
The universal collection of the intravitreal pharmacokinetic data
in rabbits was followed by determination of the primary pharma-
cokinetic parameters (CLivt and Vss, ivt). Only the studies that ful-
ﬁlled the quality criteria were included in the analysis. The CLivt and
Vss, ivt data are plotted against the molecular weight (MW) of the
compounds in Fig. 2AeB.
The Vss, ivt values in rabbits are in the range 0.72e3.14 ml.
Interestingly, there are no systematic differences in the Vss, ivt
values of small molecules and macromolecules. Overall, the scope
of Vss, ivt values is narrow (only 4-fold range) and in general the
values are slightly greater than the anatomical volume of the vit-
reous humor (1.15 ml) (Fig. 2B). Volume of vitreous is bigger than
the volumes of the surrounding tissues, such as iris, ciliary body,
choroid, retina (0.050e0.059ml) (Wiederholt et al., 1986; Wu et al.,
1970) and lens (0.33e0.53 ml) (Zamudio and Candia, 2011). The
small volumes of the tissues explain the narrow range of Vss, ivt
values (see Eqs. (1) and (2)). The highest Vss, ivt value (3.14 ml)
would be achieved with Kp (or fu, vitreous/fu, tissue) value of 2.8e4 if
we use the average combined volume for the surrounding tissues
(0.49e0.69ml) in Eq. (1) or Eq. (2), proving that Kp values in the eye
are moderate and do not have major impact on Vss, ivt values. It is
therefore likely that the new drug candidates will have Vss, ivt in the
range reported in Fig. 2B and del Amo et al. (2015). Vss, ivt values are
similar or only moderately bigger than the anatomical volume of
vitreal cavity and eye tissues, thereby ruling out the possibility that
drug partitioning to the orbita would be signiﬁcant. This is under-
standable, because the ocular blood ﬂow removes drug effectively
thereby minimizing its access to the orbita.
Drug elimination from the vitreous shows substantial differ-
ences among the compounds in the literature: CLivt values range
from 0.011 to 1.530 ml/h (139-fold difference) and the values
decrease clearly with increasing MW (Fig. 2A). Also, the t1/2, ivt
values have a broad range (del Amo et al., 2015; Kidron et al., 2012),
because the t1/2, ivt is dependent on CLivt and Vss, ivt.
The CLivt of macromolecules are low (0.011e0.027 ml/h, Fig. 2A
and D) because they are mainly eliminated via anterior route
(Fig. 1A). Interestingly, CLivt of macromolecules are clearly less than
Fig. 2. The relationships between (A) MW and CLivt and (B) MW and Vss, ivt are presented for 40 small molecular compounds and 11 macromolecules after intravitreal injections in
rabbits. The relationships between MW and CLivt of the small molecular compounds (C) and macromolecules (D) are presented. The diamonds represent the small MW compounds
with Log D7.4 below 0 (blue symbols) and Log D7.4 above 0 (red symbols). The triangles represent the macromolecules. The circles represents intravitreal clearance via permeation
across the RPE. These values were calculated based on permeability in bovine RPE-choroid membrane (Mannermaa et al., 2010; Pitkanen et al., 2005) and RPE surface area in rabbit
(Reichenbach et al., 1994) using Eq. (4). In (A) the long dashed black line represents the sum of the ocular ﬂow factors (choroidal, retinal, iridial and ciliary body blood ﬂows, and
aqueous humor ﬂow), the short dashed lines correspond to the choroidal blood ﬂow (red) and aqueous humor ﬂow (blue). In (B) the dotted line represents the anatomical volume of
the vitreous 1.15 ml. The r represent Spearman's rank correlation coefﬁcient for small drugs and macromolecules. In the original publication (del Amo et al., 2015), the phar-
macokinetic parameters of PF-04523655 were extracted from an abstract (Johnson, 2010). The original concentration curve became recently available and it was analyzed. However,
the initial concentrations were too low for the administered dose. Therefore, the parameters of this drug were omitted from the ﬁgures.
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1949) suggesting that the access of drug from the vitreous to the
anterior chamber is restricted. Presumably, CLivt of macromolecules
via posterior route through blood-retina barrier is low, due to their
low permeability in the RPE (Pitkanen et al., 2005). Intravitreal
clearance across the RPE (CLRPE) was calculated using the bovine
RPE permeability for FITC-dextrans (Pitkanen et al., 2005) and
surface area of the rabbit RPE (5.2 cm2) (Reichenbach et al., 1994)
according to Eq. (4) (P  S). These CLRPE values are 5e30 times
lower than the CLivt values for the macromolecules in the sameMW
range (Fig. 2D). This suggests that only a small fraction (3e20%) of
the macromolecule dose is eliminated through the RPE.
The wide range of CLivt of small drugs (0.031e1.530 ml/h) is
probably determined by their ability to cross the blood-ocular
barriers. High permeability across the barriers should lead to high
CLivt values. Owing to the large surface area of the RPE and high
blood ﬂow in the choroid, it is probable that the compounds with
high CLivt values are eliminated via posterior route (Fig. 1B). In our
previous studies, the t1/2, ivt and CLivt of small drugs weredetermined by H-bond capacity and LogD7.4 (del Amo et al., 2015;
Kidron et al., 2012). These descriptors typically deﬁne membrane
permeability, e.g. in the cornea (Kidron et al., 2010), intestinal wall
(Linnankoski et al., 2006) and bloodebrain barrier (Lanevskij et al.,
2009; Liu et al., 2004). Accordingly, the calculated CLRPE values for
betaxolol and carboxyﬂuorescein, using permeability values of
Pitkanen et al. (2005) and Mannermaa et al. (2010), are in the same
range with CLivt values of lipophilic and hydrophilic small mole-
cules, respectively, suggesting signiﬁcant elimination through the
RPE (Fig. 2C). Despite their ability to cross blood-retina barrier, the
CLivt values of the small molecules are far below the value of
choroidal blood ﬂow showing that clearance is permeability-
limited and not controlled by blood ﬂow (Fig. 2A).
Some clinical biologics (e.g. ranibizumab, bevacizumab) are
delivered intravitreally to the retinal and choroidal tissues. We
should note that the effects of these drugs are dependent on their
target concentrations and not on the quantity of drug that is
eliminated through the blood-retina barrier. Therefore, thera-
peutic effects in the retina and/or choroid do not mean that the
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macromolecules. Therapeutic concentrations can be reached in
the retina and/or choroid even though the posterior clearance
would be an order of magnitude less than the anterior
elimination.3. Intravitreal pharmacokinetics in human eye
Intravitreal pharmacokinetic studies in humans are sparse,
because the vitreous sampling is invasive and potentially risky
procedure. There are, however, some studies that were carried out
in patients whowere selected for vitrectomy surgery or undergoing
treatments for endophthalmitis, cytomegalovirus retinitis or
choroidal neovascularization (Table 3). Typically, these studies re-
ported only a few drug concentrations, usually from one individual
and during the terminal elimination phase of the drug. For such
data it is not possible to calculate the CLivt as it has been presented
in Section 2.3. However, we did the following exercise to get rough
estimates of CLivt (apparent CLivt), assuming one-compartment
pharmacokinetics:
apparent CL ivt ¼
Divt
AUC
(6)
where Divt is the given intravitreal dose and AUC is area under the
curve. The AUC values were calculated using equation (7):Table 3
Intravitreal drug concentrations in vitreous after intravitreal injection of drugs in human
model (section 2.3, Doc. A) and in the second panel, the apparent CLivt is calculated acco
Drugs Dose (mg) Subjects Time (h) C (mg
Bevacizumab 1250 Patients with choroidal
neovascularization
24 92.
48 165.
72 84.
96 48.
264 22.
408 0.
1032 1.
1296 0.
1776 0.
2280 0.
2424 0.
Drugs Dose (mg) Subjects
Bevacizumab 1250 Patients with choroidal neovascularization
Bevacizumab 1250 Patients with diabetic retinopathy
Cidofovir 20 AIDS patient with cytomegalovirus retinitis
Dexamethasone 383d Patients with postoperative endophthalmitis
phosphate with and without core vitrectomy
Fomivirsen 165 Patients with cytomegalovirus retinitis
Foscarnet 504d AIDS patient with cytomegalovirus retinitis
Ganciclovir 200 AIDS patient with cytomegalovirus retinitis
Ganciclovir 2000 Patients with cytomegalovirus retinitisAUC ¼ C0
k elimination
(7)
where C0 is the drug concentration in vitreous at time zero and
kelimination is the ﬁrst-order elimination rate constant. C0 was
calculated with equation (8):
C 0 ¼
Divt
V ss; ivt
(8)
where Vss, ivt was assumed to be equal to the human vitreous vol-
ume of 4 ml (Ruby et al., 2006). This is probably a reliable estimate,
because the rabbit Vss, ivt values are limited in a narrow range (80%
of the values in the dataset of 51 compoundswere between 1.18 and
2.28 ml) (del Amo et al., 2015) and close to the anatomical volume
of the vitreous. The kelimination was the slope of the curve deﬁned by
the calculated C0 and the experimental concentration values. The
apparent CLivt values are presented in Table 3. The same calcula-
tions for 2-fold higher Vss, ivt value (8 ml) were carried out and
presented in Fig. A1 (versus rabbit CLivt) and A.2 (versus MW) in
appendices. Estimation of CLivt and apparent CLivt values in human
eyes enables universal rabbit-to-human comparison of intravitreal
drug elimination (Fig. 3). Drug clearance in rabbit and human vit-
reous correlated well (r ¼ 0.91; Rabbit CLivt ¼ 1.41  Human
apparent CLivt þ 0.04, units are ml/h; R2 ¼ 0.82) and absolute dif-
ferences of the clearance values are in within 3-fold range (13/15s. In the ﬁrst panel, pharmacokinetic parameters are calculated by compartmental
rding to the description given in section 3.
/ml) Vss, ivt (ml) CLivt (ml/h) t1/2, ivt (h) References
70 3.17 0.025 160.8 (Zhu et al. 2008)
00 9.39 0.042 154.4 Own calculations
80
70
90
33
39
39
022
005
003
Time (h) C (mg/ml) Apparent CLivt
(ml/h)
References
48 166.0a 0.036 (Beer et al. 2006)
696 0.5b
672 0.107 0.028 (Moisseiev et al. 2014)
1344 0.019
24 0.673 0.336 (Taskintuna et al. 1998)
66 0.023 0.472 (Gan et al. 2005)
69 0.027
70 0.040
71 0.018
71 0.014
72 0.036
1 39.24c 0.068 (Bejanian et al. 1999)
72 10.61
168 0.39
168 0.78
336 0.26
23.25 51.53 0.152 (Diaz-Llopis et al. 1992)
51.4 1.17 0.292 (Henry et al. 1987)
24 212.0 0.172 (Morlet et al. 1996)
24 165.4
24 138.2
24 102.2
24 152.8
(continued on next page)
Table 3 (continued )
Drugs Dose (mg) Subjects Time (h) C (mg/ml) Apparent CLivt
(ml/h)
References
24 92.2
72 59.8
72 10.0
72 20.8
72 19.4
72 6.8
72 23.4
Gentamicin 50 Patients with postoperative endophthalmitis 63 0.90 0.092 (Gan et al. 2001)
with and without core vitrectomy 66 1.41
69 3.30
69 1.21
69 1.01
71 1.91
71 1.40
71 1.80
72 1.40
72 2.41
72 1.01
90 1.21
92 2.61
Vancomycin 975d Patients with postoperative endophthalmitis 44 58.11 0.068 (Ferencz et al. 1999)
with core or entire vitrectomy 48 137.85
72 182.36
72 25.05
Vancomycin 200 Patients with postoperative endophthalmitis 63 2.59 0.084 (Gan et al. 2001)
with and without core vitrectomy 66 12.07
68 10.75
69 18.03
69 8.23
69 11.97
71 15.54
71 6.30
71 9.02
71 13.28
72 8.89
72 10.10
72 6.85
90 5.80
90 3.05
92 16.59
93 4.59
Vancomycin 1000 Patients with postoperative endophthalmitis 48 125 0.100 (Haider et al. 2001)
48 164
72 21
72 83
Vancomycin 2000 Patients with postoperative endophthalmitis 48 161 0.100 (Haider et al. 2001)
72 56
72 220
72 105
72 39
Vancomycin 975d Patients with exogenous endophthalmitis 24 133.7 0.132 (Raju et al. 2004)
with core vitrectomy 24 179.0
24 171.1
48 72.5
48 43.9
Vancomycin 200 Patients with postoperative endophthalmitis 62 2.6 0.092 (Gan et al. 2005)
with and without core vitrectomy 66 12.0
68 10.8
69 12.0
69 8.2
71 15.5
71 9.0
71 8.9
71 6.3
71 16.6
72 6.8
93 4.6
Footnote.
a The patient developed endophthalmitis 2 days after the drug injection, complete drug washout of previous treatment is assumed.
b The patient suffered retinal detachment 8 days before vitreous sampling.
c Average concentration of ﬁve patients. All other reported concentrations correspond to individual patient samples and only in Morlet's study (Morlet et al. 1996) two
vitreous samples were taken from the same patient, for four patients.
d Equivalent dose.
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Fig. 4. Concentration of bevacizumab in aqueous humor versus time after intravitreal
injection in rabbit (Bakri et al., 2007; Nomoto et al., 2009) and in human eyes (Krohne
et al., 2008; Meyer et al., 2011) in arithmetic and semi-logarithmic scale.
Fig. 3. Correlation between CLivt in rabbit versus human apparent CLivt (and CLivt). The dotted and dashed lines represent 2- and 3-fold deviation and the solid line represents the
slope of 1.0. The open diamond correspond to bevacizumab CLivt calculated by Zhu et al. and the dotted one correspond to our calculations.
E.M. del Amo, A. Urtti / Experimental Eye Research 137 (2015) 111e124 119studies). The relationship of the apparent CLivt in human eye and
MW was negative (Fig. B in appendices), like in rabbits (Fig. 2A). If
higher value is used for human Vss, ivt (8 ml), the trends remain the
same, and the CLivt difference is within 4-fold range (12/15 studies)
(Fig. A1 and A2 in appendices). It is important to note that the in-
dividual values of apparent CLivt in human vitreous may not be
accurate descriptors for the elimination of individual drugs. How-
ever, Fig. 3 shows good correlation and only moderate inter-species
CLivt differences in the large pooled data from 15 studies. This
supports the use of rabbit as a model in intravitreal pharmacoki-
netic studies. It is important to note that the human patients had
different disease conditions (Table 3), but still no striking outliers
were seen in the rabbit-to-man correlation in Fig. 3.
The experiment of Zhu et al. (2008) is the only human study that
allows calculation of CLivt values with curve ﬁtting (Table 3) though
only one samplewas available for each time point. It is important to
note that bevacizumab has similar CLivt values (1.5- and 2.1-fold
differences) in rabbit and humans (Fig. 3, Doc. A).
Intravitreal pharmacokinetics in human eyes is evaluated also
by monitoring drug concentrations in the aqueous humor. Major
concentration differences of bevacizumab in aqueous humor were
seen after intravitreal injections in human (Krohne et al., 2008) and
rabbit eyes (Nomoto et al., 2009). Based on this argument, the
rabbit was considered not to be a good animalmodel for human eye
(Rowe-Rendleman et al., 2014). However, that particular rabbit
study (Nomoto et al., 2009) has some quality concerns: the ﬁrst
sample was taken only one week after the intravitreal injection and
the assayed samples had exceptionally low concentrations. The
authors compared their results with the rabbit study of Bakri et al.
(Bakri et al., 2007) and justiﬁed the concentration differences based
on the analytical method used. Nomoto et al. (2009) measured all
variants of bevacizumab (free, in complex, fragments), but this kind
of non-speciﬁc assay should lead to higher concentration values,
not lower, than in Bakri's study. Then, it is interesting to plot
together the existing rabbit and human data. The human bev-
acizumab data (Krohne et al., 2008; Meyer et al., 2011) is in line
with Bakri's levels of bevacizumab in aqueous humor (Fig. 4).
Similar conclusion is reached when AUC values of bevacizumab
(normalized to 1 mg intravitreal dose) in aqueous humor are
compared (Table 4): Nomoto's study (Nomoto et al., 2009) is clearly
an outlier. Unfortunately, much criticism against rabbit model has
been based on the comparisons of human data with Nomoto's
rabbit data.We carried out pharmacokinetic simulations of intravitreal
bevacizumab using the measured pharmacokinetic parameters
from the literature. We assumed that bevacizumab distributes in
the vitreous as indicated by the Vss, ivt values (human 9.39ml, rabbit
2.02 ml), its elimination takes place only via anterior route
(CLivt ¼ human 0.042 ml/h, rabbit 0.019 ml/h), and the elimination
from the aqueous humor (volume 0.3 ml) takes place at the rate of
aqueous humor outﬂow (human 0.14 ml/h, rabbit 0.18 ml/h) (Fig. 5,
Table 5). Since blood-aqueous barrier does not allow permeation of
proteins, the aqueous humor ﬂow remains as the only route of
bevacizumab elimination (Maurice and Mishima, 1984). The results
Table 4
The AUC values (0 e inﬁnity) of bevacizumab in aqueous humor after intravitreal injection in rabbit and human. The AUC values were dose normalized to 1 mg dose.
AUC (mg*days)/ml AUCsimulated (mg*days)/ml
Rabbit Bakri et al., 2007 234.6 231.5
Nomoto et al., 2009 7.1
Human Krohne et al., 2008 325.2 297.3
Meyer et al., 2011 131.8
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simulated bevacizumab concentrations are in line with the real
values, except the data of Nomoto et al. (Nomoto et al., 2009) that
deviates substantially from the simulations (Figs. 4 and 5). The
same conclusion is reached when AUC values of the simulations are
compared to the experimental values (Table 4).
It is important to note that the drug concentrations in the
aqueous humor are different from the concentrations in the vitre-
ous. Moreover, the ratio of the concentrations (aqueous humor/
vitreous) may not be constant for all compounds. Based on simu-
lation, AUCaqueous humor/AUCvitreous for small lipophilic compound
(CLivt ¼ 0.5 ml/h, CLaqueous humor ¼ 1.2 ml/h (Schoenwald, 2003)) is
0.016. This means that the drug concentrations in the vitreous are
approximately 50 times greater than in the aqueous humor. In the
case of bevacizumab, the AUC-ratio is 0.095 meaning that
approximately 10-fold higher concentrations are seen in the vit-
reous than in the aqueous humor.4. Role of the vitreous in intravitreal pharmacokinetics
Many studies suggest that the vitreous plays a role in ocular
pharmacokinetics, because the clearance of small MW drugs is
faster in vitrectomized and lensectomized rabbit eyes than in either
lensectomized or control rabbit eyes (Doft et al., 1985; Ficker et al.,
1990; Jarus et al., 1985; Mandell et al., 1993; Pearson et al., 1993;
Pﬂugfelder et al., 1987; Wingard et al., 1989). However, there are
many changing variables in such studies (Doft et al., 1985; Ficker
et al., 1990; Mandell et al., 1993; Wingard et al., 1989), and it is
impossible to distinguish the speciﬁc effects of vitreous from the
experiments with vitrectomized and lensectomized eyes (JarusFig. 5. The model structure and simulated bevacizumab concentrations in the human
(in red) and rabbit (in black) aqueous humor are presented. The doses are as described
in Fig. 3. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)et al., 1985; Pearson et al., 1993; Pﬂugfelder et al., 1987). There
are a few studies with vitrectomized rabbit eyes without lensec-
tomy (Ahn et al., 2013, 2014; Christoforidis et al., 2013; Lee et al.,
2010). In vitrectomized rabbit eyes, pharmacokinetics of bev-
acizumab and ranibizumab did not differ from the control rabbits
(Ahn et al., 2013, 2014), while in another study small (1.8- and 1.3-
fold) differences were seen for bevacizumab and ranibizumab,
respectively (Christoforidis et al., 2013). Likewise, small increase in
the elimination of FITC-dextrans was shown in the rabbit eyes after
hyaluronidase treatment (Tan et al., 2011). We must be cautious in
the interpretations because vitrectomy or enzyme treatment may
endanger the integrity of the blood-ocular barriers (Knudsen et al.,
2001; Mochizuki et al., 1992, 1993).
Lee et al. (Lee et al., 2010) claimed a 10 times shorter t1/2, ivt for
the vitrectomized rabbit as compared to the control rabbit. How-
ever, this study is misleading and data analysis is not reliable. In the
operated eye, the half-life was calculated based on two experi-
mental early data points, while additional later time point was
included in the data analysis of the control eye. Moreover, the
calculated t1/2, ivt in the control group was abnormally short
considering that VEGF is a macromolecule. This problem has also
been pointed out in other publications (Ahn et al., 2013, 2014). In
conclusion, the study of Lee et al. (Lee et al., 2010) is an outlier
among the studies on the vitreous effects on ocular pharmacoki-
netics. Most data does not support signiﬁcant role of vitreous in
drug elimination from the vitreous cavity.
Relatively minor effects of vitreous on ocular pharmacokinetics
is understandable, because the vitreous is relatively loose structure
that allows rapid diffusion of small molecular drugs and proteins
(Gajraj, 2012; Maurice and Mishima, 1984; Pitkanen et al., 2003; Xu
et al., 2000). Recently the mean pore size of the vitreous was
analyzed to be 550 ± 50 nm, value that is two orders of magnitude
greater than typical molecular diameter of a protein drug (Xu et al.,
2013). Therefore, changes in the vitreous viscosity are not expected
to have effects on drug diffusion and drug elimination from the eye.
For example, diffusivity in the porcine and rabbit vitreous was
similar (Gajraj, 2012) even though these species have difference in
the viscosity of the vitreous. Furthermore, CLivt values show 139-
fold range in vivo in rabbits (Fig. 2A). Compared to that range, the
differences in the drug diffusion in the vitreous are negligible
(Gajraj, 2012; Missel, 2012; Xu et al., 2000). Importantly, molecular
permeability in the isolated RPE-choroid had 618-fold range of
values depending on the lipophilicity and size of the compound
(Pitkanen et al., 2005). Overall, permeability in the blood-retina
barrier deﬁnes the range of CLivt values of drugs after intravitreal
injections. In the case of small molecules, there is no correlation
between MW and CLivt (Fig. 2C), but QSPR model with hydrogen
bonding and LogD7.4 describes the CLivt reliably (del Amo et al.,
2015) showing clear dependence on blood-ocular barrier
permeation.
Formacromolecules the range of CLivt values is only about 3-fold,
even though the MW range is 7122e149,000 (Fig. 2D). The CLRPE
values are much smaller than CLivt values indicating dominating
role of the anterior elimination route, but yet CLivt values are clearly
smaller than the rate of aqueous humor turnover (Fig. 2D). This is
mainly due the restricted access of the drug from vitreous to the
Table 5
Comparison between the pharmacokinetically relevant anatomical and physiological parameters in the rabbit and human (or monkey) eye. The factors affecting the CLivt of
macromolecules are marked by a dotted box. All parameters may affect the CLivt of small molecular drugs.
Rabbit Human  References 
Physiological 
values 
affecting  
CLivt 
B
lo
od
 fl
ow
 
m
ed
ia
te
d 
C
L i
vt
Barrier surface area Surface area of RPE 520a mm2 1204 ± 184b mm2 (Reichenbach et al. 1994) (Panda-Jonas et al. 1994) 
Barrier permeability TEER of RPE layer 179.2 ± 6 ohm.cm2 79 ± 48 ohm.cm2 (Koyano et al. 1993) (Quinn and Miller. 1992) 
Choroidal blood flow 62 ml/h 43 ml/h (Nilsson and Alm. 2012) (Sebag et al. 1994) 
Blood flows: Retinal blood flow 0.66 ml/h 0.26 ml/h (Nilsson and Alm. 2012) (Feke et al. 1989)  
Ciliary body blood flow 4.91 ml/h 5.34c ml/h (Nilsson and Alm. 2012) (Alm and Bill. 1973) 
Iridial blood flow 3.72 ml/h 1.02c ml/h (Nilsson and Alm. 2012) (Alm and Bill. 1973) 
A
qu
eo
us
 
hu
m
or
 fl
ow
 
m
ed
ia
te
d 
C
L i
vt
Aqueous humor flow 0.18 ml/h 0.14 ml/h (Barany and Kinsey. 1949) (Brubaker. 1982) 
Barrier between vitreous and anterior chamber undefined  undefined 
Physiological values 
affecting Vss, ivt of all 
drugs 
Ocular volumes: Vitreous volume 1.15 ml 4 ml (del Amo et al. 2015) (Ruby et al. 2006) 
Lens weight 0.33 - 0.53 g 0.15 - 0.26 g 
(Zamudio and Candia. 2011) 
(Hemenger et al. 1995) 
Uveal tract & retina weight 0.16 g (Wiederholt et al. 1986) 
Choroid weight 0.059 g (Wu et al. 1970) 
Iris weight 0.057 g (Wu et al. 1970) 
Ciliary body weight 0.050 g (Wu et al. 1970) 
Tissue affinities: Kp, ocular tissues No data No data 
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and partly due to the diffusion in the vitreous. Even though CLivt
values of macromolecules may partly depend on their diffusivity in
the vitreous, the values are spanning only a narrow range despite
the large differences in the MWs. This is not surprising, because the
pore size of non-liqueﬁed vitreous (550 nm) is far greater than the
size of protein drugs (about 5e10 nm) (Xu et al., 2013). Interestingly,
CLivt values do not correlate with MW (Fig. 2D). This suggests that
the role of vitreous may be related to the vitreouseproteins in-
teractions, and not size related sieving effects.
Vitreous may have more signiﬁcant effects on intravitreal
pharmacokinetics in special cases. For example, highly cationic
macromolecules, cationic nanoparticles and larger suspension
particles show limited mobility and possible aggregation in the
vitreous (Chin et al., 2005; Doft et al., 1985; Pitkanen et al., 2003;
Wingard et al., 1989; Xu et al., 2013). These formulation aspects
are, however, beyond the scope of this article.
5. Rabbit as an animal model in intravitreal
pharmacokinetics
Successful translation of intravitreal pharmacokinetics from
rabbit to man requires quantitative understanding of intravitreal
pharmacokinetics in both. Unfortunately, there are only sparse data
on human intravitreal pharmacokinetics. As presented in Sections 2
and 3, we have pooled all available data to calculate the primary
pharmacokinetic parameters for the rabbit and human eye. The
outcome does not support the criticism of rabbit as an animal
model. Rather, it indicates that in general rabbit is a decent model
in the vitreal pharmacokinetics.
Vss, ivt values depend on the anatomical volumes of the vitreousand surrounding tissues, and drug partitioning to the tissues
(Section 2.1). Like in the rabbits, the human Vss, ivt values are ex-
pected to be close to human vitreous volume (4 ml), since the
adjacent tissues are very small compared to the vitreous volume.
Indeed, for bevacizumab (Zhu et al., 2008) the Vss, ivt in humanwas
calculated as 3.2 ml and 9.4 ml (Table 3). These values were 1.6-fold
and 4.5-fold higher than the Vss, ivt in rabbit (2.0 ml) (Bakri et al.,
2007; Christoforidis et al., 2013; del Amo et al., 2015), while the
difference in the vitreous volumes is between 2- and 3-fold
(Table 5). Recently, Krohne et al. (2015) did not ﬁnd signiﬁcant
impact of axial length and lens status on the pharmacokinetics of
intravitreal ranibizumab and bevacizumab. This supports the
notion that the Vss, ivt is relatively constant, mostly governed by the
volume of the vitreous. On the contrary, systemic volumes of drug
distribution span approximately 200,000-fold range (Obach et al.,
2008). In conclusion, Vss, ivt in humans can be estimated with
good accuracy based on the rabbit data and size difference of hu-
man and rabbit eye.
CLivt for small lipophilic molecules takes place mostly via RPE
and choroid (Maurice andMishima,1984). The choroidal blood ﬂow
values in the rabbit and human are quite similar being about 85% of
the total ocular blood ﬂow (Table 5). It is known that both CLivt and
RPE permeability are strongly affected by lipophilicity indicator
(LogD7.4) of the drug (del Amo et al., 2015; Pitkanen et al., 2005).
Indeed, CLivt via RPE should be the product of drug permeability in
the RPE and surface area of the RPE (Section 2.1, Eq. (4)). The RPE
permeability in rabbit and human should be similar due to their
similar trans-epithelial electrical resistance (TEER) values (Table 5),
while the area of RPE is two to three times higher than in the rabbit.
Therefore, CLivt of small lipophilic compounds is expected to be two
or three times higher in man than in rabbit. This trend was
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times greater than the CLivt in rabbits. Anyway, the values are
relatively similar and the correlation is good (r ¼ 0.91, R2 ¼ 0.82).
One criticism has been based on the differences between the
vasculature of the rabbit retina and the human retina. Nevertheless,
in rabbit and human the retinal and choroidal blood ﬂows are
similar (Table 5) and the vascular walls as well (tight junctions in
the retina; leaky vessels in the choroid). However, some issues of
concern are related to the potential impact of the disease state on
leakiness of the bloodeocular barriers, especially the RPE. Since
CLivt is clearly permeability limited, changes in the rateelimiting
membranes are expected to modify pharmacokinetics. This factor
did not become evident in the data analysis based on the patients in
Fig. 3, but we cannot exclude the possibility that some disease
states might have signiﬁcant impact on the intravitreal
pharmacokinetics.
For macromolecules, anterior elimination via aqueous humor
turnover is the main route of elimination. The rates of the aqueous
humor turnover are similar in human and rabbit (Table 5), but these
values are higher than the CLivt of macromolecules (Dejneka et al.,
2008; del Amo et al., 2015; Eyetech Study Group, 2002; Leeds et al.,
1997). Therefore, the access of the drug to the aqueous humor may
limit its elimination in both rabbit and human eye. The CLivt values
of bevacizumab in humans are 0.025 ml/h and 0.042 ml/h (Table 4),
while in rabbit it is 0.019 ml/h (Bakri et al., 2007; Christoforidis
et al., 2013; del Amo et al., 2015). The role of the barrier between
vitreous and anterior chamber (lens, vitreous, zonules) remains
unknown, but the data do not support major differences between
man and rabbit.
In humans, the vitreous becomes more liqueﬁed and less ho-
mogenous with the age, and this is associated with increased
convective ﬂow in the vitreal cavity (Maurice, 2001; Missel, 2012).
Liquefaction and convection has been stated to be major pharma-
cokinetic differences between the rabbit and elderly patients
(Laude et al., 2010). However, no signiﬁcant difference in the
intravitreal concentrations in patients with and without vitrectomy
was observed in Gan's study (Gan et al., 2005) and the apparent
CLivt value of vancomycin was not higher in vitrectomized patients
(Ferencz et al., 1999) compared to non-vitrectomized patients
(Haider et al., 2001) (Fig. 3, Table 2). Moreover, apparent CLivt values
in elderly patients with and without vitrectomy were only
moderately different from the CLivt values in healthy rabbits (Fig. 3,
Table 2). Furthermore, Los (2008) showed that aging rabbit eyemay
be a good model for human vitreous liquefaction based on
anatomical and histological analysis. Such a model may be a better
approach than enzyme treatments to investigate the effect of the
liquefyingmatrix or vitrectomy on vitreal drug elimination. Overall,
even though vitreous humor may play a partial role in the elimi-
nation of macromolecules from the vitreal cavity, there is no evi-
dence that the differences in the vitreal liquefaction or convection
would cause signiﬁcant changes in intravitreal pharmacokinetics
(Fig. 3).
Drug metabolism in the liver is different in various species and,
therefore, test methods based on human cells are being developed
(Vellonen et al., 2014). The metabolic activity in the eye is relatively
small if any. In general, intravitreal drugs are eliminated from the
eye via elimination across the blood-ocular barriers and aqueous
humor outﬂow, and not via metabolism (del Amo et al., 2015).
Comparison between the rabbit and human data has not revealed
metabolism derived species differences in vitreal drug elimination.
Even though the eye is partly immune protected site, there is a
possibility that intravitreal injection of human protein or human-
ized antibody could cause immune response in the eye. Impact of
immune response on intravitreal pharmacokinetics has not been
demonstrated, even though Gaudreault et al. (2007) discussed thispossibility. Formation of anti-drug antibodies can have substantial
inﬂuence on systemic clearance of some protein-based drugs (Chen
et al., 2013). The neutralizing antibodies are formed in a fewweeks.
Therefore, the immunological inﬂuence on intravitreal pharmaco-
kinetics is expected to be minimal after a single injection, but may
become evident during multiple dosing therapy.
Sometimes binding of drug to target proteins determines the
drug clearance from the systemic circulation (Levy, 1994). For
example, FcRN receptors mediate clearance of monoclonal anti-
bodies from the systemic circulation so that the receptor turnover
processes bring drug back to the blood circulation thereby pro-
longing the retention in the circulation (Ezan, 2013; Mager and
Jusko, 2001). This leads sometimes also to receptor saturation
and dose-dependent clearance, i.e. increasing clearance at higher
doses. In principle, such mechanisms might operate within the eye,
but so far they have not been shown to exist.
This review has concentrated on intravitreal pharmacokinetics
of drugs in solution form. There is an increasing interest on ocular
drug delivery systems for prolonged and controlled drug delivery to
the posterior eye segment (del Amo and Urtti, 2008). The func-
tionality of the dosage forms in the rabbit and human eye is beyond
the scope of this review. Anyway, CLivt values are useful in the
design of drug delivery systems, because the required release rate
in vivo depends on the target concentration and CLivt (del Amo
et al., 2015). Furthermore, the required drug payload in the
dosage form is release rate multiplied by the dosing interval. As
only small volumes can be injected intravitreally (maximum
100 ml), computational estimation of drug payload is very impor-
tant aid in the design of prolonged action dosage forms for the
retinal treatment. Overall, CLivt should be taken into account in the
design of new intravitreal drug delivery systems.
6. Conclusions
In this review we have analyzed the data on intravitreal phar-
macokinetics in rabbits and humans. Overall, based on the current
data the rabbit is clinically predictable animal model for intravitreal
pharmacokinetics, since both intravitreal volume of distribution
and clearance values differ only moderately between rabbit and
human. Intravitreal pharmacokinetic studies should be designed so
that accurate values for clearance and volume of distribution are
obtained. Further studies are needed in special cases, such as dis-
ease state effects, to complement the understanding of intravitreal
pharmacokinetics.
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